Alkem Laboratories Limited — Important, 17-12-2024: General Updates

Alkem Laboratories, in collaboration with its subsidiary Enzene Biosciences, has entered into a Share Subscription and Shareholders’ Agreement with Sunsure Solarpark and Sunsure Energy for an equity investment in Sunsure Solarpark. This investment marks a strategic move into the renewable energy sector, enabling Alkem and Enzene to collectively hold at least a 26% stake in Sunsure Solarpark by the end of April 2025.

Sunsure Solarpark, which is yet to commence commercial production, will leverage the investment to become a captive user of renewable energy, aiming to drive down power costs and adhere to environmental governance standards. The total investment amounts to ₹1.95 crore, with Alkem contributing ₹0.936 crore for a 12.48% stake, while Enzene will invest ₹1.014 crore for a 13.52% stake. This initiative represents a proactive step towards cost-effective energy solutions that align with sustainability goals, presenting a positive outlook for Alkem’s energy strategy.